Aller au contenu

Boehringer's Survodutide Did Not Raise Heart Risk in a 5,530-Person Phase 3 Safety Trial, as Boehringer Moves Toward Obesity Filings

12 novembre 2026 · 5 min

Notes de l’épisode

Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial, presented at the American Heart Association's Scientific Sessions 2026 and published in The Lancet on November 9, 2026. The cardiovascular safety trial enrolled 5,530 adults with overweight or obesity and heart disease, chronic kidney disease, or at least two weight-related risk factors. The main combined endpoint (cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularization or heart failure event) occurred in 3.7% of people on survodutide and 4.1% on placebo (hazard ratio 0.89, 95% CI 0.67 to 1.18), meeting the goal of showing no increase in risk; the trial was not designed to show a heart benefit. Under the supplementary estimand at 72 weeks, weight fell by up to 13.7% versus 2.0% with placebo, systolic blood pressure by up to 6.68 versus 1.76 mmHg, and waist size by up to 11.96 versus 2.74 cm. Nausea and vomiting were far more common on survodutide, and 19.3% and 20.8% of people in the two survodutide arms stopped treatment because of gastrointestinal side effects, versus 1.9% on placebo; serious adverse events were similar across groups. Survodutide is not approved anywhere. Boehringer, which funded the trial, says it is moving toward regulatory submissions in obesity and told Fierce Biotech it aims to file for weight loss in the next year.

Sources

  • Boehringer Ingelheim press release (Nov 9, 2026), survodutide SYNCHRONIZE-CVOT results: globenewswire.com
  • The Lancet (Nov 9, 2026), Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT), abstract on PubMed: pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov, NCT06077864 (SYNCHRONIZE-CVOT): clinicaltrials.gov
  • Fierce Biotech (Nov 9, 2026), AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test: fiercebiotech.com
  • AJMC (Nov 9, 2026), Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT: ajmc.com

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

Tous les épisodes de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Paramètres

Affichage

Langue

Détermine les stations affichées en premier sur la page d’accueil.

Historique

Les stations et épisodes écoutés récemment et tes dernières recherches sont seulement enregistrés dans ce navigateur.

Notifications

Un court message quand un podcast que tu suis publie un nouvel épisode. Désactive un podcast précis avec la cloche sur sa page.

Compte

Enregistrez vos favoris – dans l’app et sur le site.

Raccourcis clavier

/
Ouvrir la recherche
Espace
Lecture ou pause
← →
Dans le lecteur : 15 s en arrière, 30 s en avant (épisodes) · dans une rangée : tuile suivante
↑ ↓
Dans une rangée : cible dans la tuile
Début / Fin
Dans une rangée : première ou dernière tuile
Esc
Fermer la fenêtre ou le menu
?
Cet aperçu
En cours de lecture

Voir la station

À suivre

    Ajoutez des épisodes avec « À suivre » – ils seront lus après l'épisode en cours.